Chronic inflammation links fragile bones and dementia

Osteoporosis and cognitive decline are typically treated as separate aging conditions. But the data point to a real connection: people with osteoporosis face roughly twice the risk of cognitive impairment. People with cognitive impairment face one and a half times the risk of bone loss, with Alzheimer’s disease carrying the highest risk. These numbers suggest a shared driver rather than a direct causal relationship between the two.

Inflammation as the shared mechanism

Researchers present, in this review published in Frontiers in Immunology, a framework in which chronic low-grade inflammation, called inflammaging, is the connecting thread. The study describes how senescent cells that secrete inflammatory signals (the so-called SASP, or senescence-associated secretory phenotype) drive both bone breakdown and brain inflammation. Key signaling molecules including IL-6, IL-1β, and TNF-α activate both bone-degrading cells (osteoclasts) and the brain’s resident immune cells (microglia).

Bone tissue also sends signals to the brain. With age, production of osteocalcin, a bone-derived protein with beneficial effects on the brain, declines, while sclerostin rises. This may disrupt the Wnt/β-catenin signaling pathway, which helps maintain healthy brain tissue.

Interventions remain unproven

The researchers discuss several candidate treatments that might target both systems, including senolytic agents such as dasatinib and quercetin, anti-inflammatory drugs, GLP-1 receptor agonists, and microbiome strategies. They emphasize explicitly that none of these qualifies as a proven co-therapy for bone-brain disease. These are directions for clinical research, not recommendations.

From a longevity perspective, the key takeaway of this study is significant: if one underlying process, age-related chronic inflammation, simultaneously damages bone and brain, then early intervention on that process may be most effective for both conditions.

Read the original article